- Achieved statistical significance versus standard-of-care (SOC) control across all key efficacy endpoints in the 52-week study- Japan Phase 3 results strengthen CARTISTEM's® global commercial prospects, with Japan biologics license application (BLA) scheduled for 2H 2026 SE